| Role of macrophage targeting in the antitumor activity of trabectedin G Germano, R Frapolli, C Belgiovine, A Anselmo, S Pesce, M Liguori, ... Cancer cell 23 (2), 249-262, 2013 | 867 | 2013 |
| Blood pressure variability and organ damage in a general population: results from the PAMELA study R Sega, G Corrao, M Bombelli, L Beltrame, R Facchetti, G Grassi, ... Hypertension 39 (2), 710-714, 2002 | 448 | 2002 |
| Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections S Marchini, D Cavalieri, R Fruscio, E Calura, D Garavaglia, IF Nerini, ... The lancet oncology 12 (3), 273-285, 2011 | 220 | 2011 |
| Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy FM Noe, N Polascheck, F Frigerio, M Bankstahl, T Ravizza, S Marchini, ... Neurobiology of disease 59, 183-193, 2013 | 188 | 2013 |
| Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer S Marchini, R Fruscio, L Clivio, L Beltrame, L Porcu, IF Nerini, D Cavalieri, ... European journal of cancer 49 (2), 520-530, 2013 | 184 | 2013 |
| Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy V Iori, AM Iyer, T Ravizza, L Beltrame, L Paracchini, S Marchini, M Cerovic, ... Neurobiology of disease 99, 12-23, 2017 | 169 | 2017 |
| Mode of action of trabectedin in myxoid liposarcomas S Di Giandomenico, R Frapolli, E Bello, S Uboldi, SA Licandro, S Marchini, ... Oncogene 33 (44), 5201-5210, 2014 | 137 | 2014 |
| Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion V Santarlasci, L Maggi, M Capone, V Querci, L Beltrame, D Cavalieri, ... Immunity 36 (2), 201-214, 2012 | 136 | 2012 |
| Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation A Aldinucci, L Rizzetto, L Pieri, D Nosi, P Romagnoli, T Biagioli, ... The Journal of Immunology 185 (9), 5102-5110, 2010 | 126 | 2010 |
| Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models C Belgiovine, E Bello, M Liguori, I Craparotta, L Mannarino, L Paracchini, ... British Journal of Cancer 117 (5), 628-638, 2017 | 122 | 2017 |
| Bone marrow fibroblasts overexpress miR‐27b and miR‐214 in step with multiple myeloma progression, dependent on tumour cell‐derived exosomes MA Frassanito, V Desantis, L Di Marzo, I Craparotta, L Beltrame, ... The Journal of Pathology 247 (2), 241-253, 2019 | 85 | 2019 |
| IL‐4‐induced gene 1 maintains high T ob1 expression that contributes to TCR unresponsiveness in human T helper 17 cells V Santarlasci, L Maggi, A Mazzoni, M Capone, V Querci, MC Rossi, ... European journal of immunology 44 (3), 654-661, 2014 | 84 | 2014 |
| Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile I Cifola, R Spinelli, L Beltrame, C Peano, E Fasoli, S Ferrero, S Bosari, ... Molecular cancer 7 (1), 1-12, 2008 | 84 | 2008 |
| The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus R Vįzquez, ME Riveiro, L Astorgues-Xerri, E Odore, K Rezai, E Erba, ... Oncotarget 8 (5), 7598, 2017 | 83 | 2017 |
| MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities E Calura, R Fruscio, L Paracchini, E Bignotti, A Ravaggi, P Martini, ... Clinical cancer research 19 (15), 4114-4123, 2013 | 75 | 2013 |
| Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism L Rizzetto, M Kuka, C De Filippo, A Cambi, MG Netea, L Beltrame, ... The Journal of Immunology 184 (8), 4258-4268, 2010 | 74 | 2010 |
| Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts P Todeschini, E Salviato, L Paracchini, M Ferracin, M Petrillo, L Zanotti, ... Cancer Letters 388, 320-327, 2017 | 73 | 2017 |
| Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective … M Petrillo, GF Zannoni, L Beltrame, E Martinelli, A DiFeo, L Paracchini, ... Annals of Oncology 27 (4), 625-634, 2016 | 73 | 2016 |
| FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients RA Tassi, P Todeschini, ER Siegel, S Calza, P Cappella, L Ardighieri, ... Journal of Experimental & Clinical Cancer Research 36, 1-18, 2017 | 67 | 2017 |
| lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: A retrospective and multicentric study P Martini, L Paracchini, G Caratti, M Mello-Grand, R Fruscio, L Beltrame, ... Clinical Cancer Research 23 (9), 2356-2366, 2017 | 66 | 2017 |
Chiara RomualdiDipartimento Biologia, Universitą di PadovaVerified email at unipd.it
